S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Paruchuri, Vikram ^a   Prasad, Anil ^a   McHugh, Kevin ^a   Bhat, Hari K ^b   Polyak, Kornelia ^a   Ganju, Ramesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 8; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; PSORIASIN; SHORT HAIRPIN RNA; TYROSINE; CALCIUM BINDING PROTEIN; COLLAGEN; ERBB2 PROTEIN, MOUSE; LAMININ; MATRIGEL; PROTEOGLYCAN; S100A7 PROTEIN, HUMAN; S100A7 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIBIA; TUMOR VASCULARIZATION; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG COMBINATION; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHOSPHORYLATION; VASCULARIZATION; WESTERN BLOTTING;

MUS;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-8; LAMININ; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OSTEOCLASTS; OSTEOLYSIS; PHOSPHORYLATION; PROTEOGLYCANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TYROSINE;

EID: 45849145817     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001741     Document Type: Article

References (46)

1. Madsen P, Rasmussen HH, Leffers H, Honoré B, Dejgaard K, et al. (1991) Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J Invest Dermatol 97: 701-12.
2. Moubayed N, Weichenthal M, Harder J, Wandel E, Sticherling M, et al. (2007) Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours. J Cancer Res Clin Oncol; 133: 253-61.
3. Alowami S, Qing G, Emberley E, Snell L, Watson PH (2003) Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol; 3: 1.
4. Webb M, Emberley ED, Lizardo M, Alowami S, Qimhg G, et al. (2005) Expression analysis of the mouse S100A7/psoriasin gene in skin inflamination and mammary tumorigenesis. BMC Cancer; 5: 17.
5. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, et al. (1997) Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res; 57: 4111-117.
6. Al-Haddad S, Zhang Z, Leygue E, Snell I., Huang A, et al. (1999) Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol; 155: 2057-66.
7. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, et al. (2003) Molecular markers in ductal carcinoma in situ ofthe breast. Mol Cancer Res; 1: 362-75.
8. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, et al. (2005) The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res; 65: 5696-702.
9. Liu E, Thor A, He M, Barcos M, Ljung BM, et al. (1992) The HEM (c-erbB-2) oncogene is frequently amplified in situ carcinomas of the breast. Oncogene; 7: 1027-32.
10. Khazaie K, Schirrmacher V, Lichmer RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev; 12: 255-74.
11. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, et al. (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res; 1: 19-31.
12. Silva AR (2006) Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation Int J Surg Pathol; 14: 268; author reply 269.
13. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res; 284: 31-53.
14. Krop I, Marz A, Carlsson H, Li X, Bloushtain-Qimron N, et al. (2005) A putative role for psoriasin in breast tumor progression. Cancer Res; 65: 11326-34.
15. Harvey HA (1997) Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer; 80: 1646-51.
16. Yoneda T, Sasaki A, Mundy GR (1994) Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat; 32: 73-84.
17. Bendre M, Gaddy D, Nicholas RW, Suva LJ (2003) Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res; S39-45.
18. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, et al. (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res; 62: 5571-79.
19. Brandt BH, Roetger A, Dittmar T. Nikolai G, Seeling M. et al. (1999) c-crbB-2/EGFR as dominant heterodimerization partners determine a Mitogenic phenotype in human breast cancer cells. Faseb J; 13: 1939-49.
20. Carpenter G (2000) The EGF receptor: a nexus for trafficking and signaling. Bioessays; 22: 697-707.
21. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, et al. (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J; 15: 254-64.
22. Di Giovanna. MP, Stern DF, Edgerton SM, Whalen SG, Moore D, et al. (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol; 23: 1152-60.
23. Dimri M, Naramura M, Duam L, Chen J, Ortega-Cava C, et al. (2007) Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res; 67: 4164-72.
24. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, et al. (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res; 63: 2940-47.
25. Angelucci A, Gravina GL, Rucci, Millimaggi D, Festuccia C, et al. (2006) Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer; 13: 197-210.
26. Emberley ED, Niu Y, Njue C, Kliewer EV, Murphy LC, et al. (2003) Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res; 9: 2627-31.
27. Bryborn M, Adner M, Cardell LO (2005) Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and non-allergic individuals using 2-dimensional gel electrophoresis and mass spectrometry. Respir Res; 6: 118.
28. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, et al. (2003) Psoriasin interacts with Jabl and influences breast cancer progression. Cancer Res; 63: 1954-61.
29. Bertics PJ, Chen WS, Hubler L, Iazar CS, Rosenfeld MG, et al. (1988) Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation. J Biol Chem; 263: 3610-17.
30. Lombardo CR, Consler TG, Kassel DB (1995) In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites: Biochemistry; 34: 16456-66.
31. Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, et al. (2006) Her-2/neu and EGFR tyrosinc kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer; 118: 1126-34.
32. Ostman A, Hellberg C, Bohmer FD (2006) Protein-tyrosine phosphatases and cancer. Nat Rev Cancer; 6: 307-20.
33. Lu W, Gong D, Bar-Sagi D, Cole PA (2001) Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell; 8: 759-69.
34. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, et al. (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer; 95: 1410-14.
35. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, et al. (1992) Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res; 52:4,773-78.
36. Hennipman A, van Oirschot BA, Smits J, Rijksen G, Staal GE (1989) Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res; 49: 516-21.
37. Lotz M, Wang HH. Cance W, Matthews J, Pories S (2003) Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion. J Surg Res; 109: 123-29.
38. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. (1999) Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res; 59: 5849-55.
39. Guise TA, Kozlow WM, Heras-Herziga, Padalecki SS, Yin JJ, et al. (2005) Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer; 5 Suppl: S46-53.
40. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer; 97: 834-39.
41. Roodman GD, (2001) Biology of osteoclast activation in cancer. J Clin Oncol; 19: 3562-71.
42. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissig_ere, et al. (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Rs; 9: R15.
43. Singh B, Berry JA, Vincent LE, Lucci A (2006) Involvement of 11-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res; 134: 44-51.
44. Chelouche-Lev D, Miller CP, Tellez C, Ruiz M, Bar-Eli M, et al. (2004) Different signalling pathways regulate VEGF and 11-8 expression in breast cancer. implications for therapy. Eur J Cancer; 40: 2509-18.
45. Vogl G, Bartel N, Dietze O, Hauser-Kronberger C (2006) HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immmunohistochem Mol Morphol; 14: 138-45.
46. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, et al. (2006) ErbB2 increases vascular endothelial grolh factor protein synthesis via activation of mammalian target of Rapanycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res; 66: 2028-37.